Get the Stockscreener App
7.43
3.13%
-0.24
After Hours:
7.43
Adaptive Biotechnologies Corp stock is traded at $7.43, with a volume of 1.89M.
It is down -3.13% in the last 24 hours and down -10.05% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$7.67
Open:
$7.27
24h Volume:
1.89M
Relative Volume:
1.16
Market Cap:
$1.12B
Revenue:
$177.28M
Net Income/Loss:
$-195.24M
P/E Ratio:
-5.5448
EPS:
-1.34
Net Cash Flow:
$-114.54M
1W Performance:
-14.20%
1M Performance:
-10.05%
6M Performance:
+45.12%
1Y Performance:
+131.46%
1-Day Range:
$7.1126
$7.68
1-Week Range:
$7.1126
$8.74
52-Week Range:
$2.28
$9.01
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
7.43 | 1.12B | 177.28M | -195.24M | -114.54M | -1.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Swiss National Bank Takes $1.22 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Proficio Capital Partners LLC Takes Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Corp: Analyzing ADPT Stock Trends - investchronicle.com
Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief scientific officer sells shares for $15,282 - Investing.com India
Charles Schwab Investment Management Inc. Acquires 39,831 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies stock hits 52-week high at $8.95 By Investing.com - Investing.com Australia
Adaptive Biotechnologies stock hits 52-week high at $8.95 - Investing.com
Amundi Boosts Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up – What’s Next? - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World
Bank of New York Mellon Corp Has $2.18 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Gains Following Goldman Sachs Upgrade, Share Climb 6% Near Friday Close - MarketScreener
Analyst Expectations For Adaptive Biotechnologies's Future - Benzinga
Scholastic Posts Strong Earnings, Joins Ouster, Torrid Holdings, Adaptive Biotechnologies And Other Big Stocks Moving Higher On Friday - Benzinga
Goldman Sachs Upgrades Adaptive Biotechnologies to Buy From Neutral, Adjusts Price Target to $9 From $8 - Marketscreener.com
Goldman Sachs Upgrades Adaptive Biotechnologies (ADPT) - MSN
Adaptive Biotechnologies (ADPT): Among Stocks Insiders Are Selling In March - Insider Monkey
10 Stocks Insiders Are Selling In March - Insider Monkey
Proficio Capital Partners LLC Takes $93,000 Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.1% on Insider Selling - Defense World
Adaptive Biotechnologies director sells shares worth $70,500 By Investing.com - Investing.com Canada
Adaptive Biotechnologies director sells shares worth $70,500 - Investing.com India
Adaptive Biotechnologies director sells shares worth $402,270 - Investing.com
Adaptive Biotechnologies Executives Sell Shares - TradingView
Minimal Residual Disease Market Expected to rise, 2032 | Adaptive Biotechnologies, Bristol-Myers Squibb Company, Natera, Kite Pharma, Amgen Inc., expected to boost the market - Barchart
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma - The Manila Times
US Bancorp DE Sells 43,819 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Insider Selling: Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Sells $819,109.98 in Stock - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% on Insider Selling - Defense World
Adaptive Biotechnologies director sells $124,372 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CEO Chad Robins sells $1.6 million in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Purchases Shares of 143,444 Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies president Julie Rubinstein sells $415,539 in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CFO sells shares worth $72,072 By Investing.com - Investing.com South Africa
Adaptive Biotechnologies’ chief scientific officer sells $675k in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies chief people officer sells $145,845 in stock - Investing.com
Adaptive Biotechnologies chief people officer sells $145,845 in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies director sells $124,372 in stock - Investing.com India
Adaptive Biotechnologies president Julie Rubinstein sells $415,539 in stock - Investing.com
Adaptive Biotechnologies’ chief scientific officer sells $675k in stock - Investing.com
Adaptive Biotechnologies’ chief commercial officer Sharon Benzeno sells $311,792 in stock - Investing.com
Private Advisor Group LLC Makes New $264,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Holdings Increased by Rhumbline Advisers - Defense World
D.A. Davidson & CO. Buys 6,725 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Adaptive Biotechnologies’ (ADPT) “Overweight” Rating Reiterated at Piper Sandler - Defense World
Cathie Wood’s Ark Invest Makes Bold Moves: Buys BEAM & NU, Sells MELI & ADPT - Apna Kal
Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive BiotechnologiesARK Fintech Innovation ETF (ARCA:ARKF), Adaptive Biotechnologies (NASDAQ:ADPT) - Benzinga
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):